

----- Forwarded message -----

From: **Patel, Sunil** <sunil.patel@bms.com>

Date: Tue, Sep 16, 2014 at 3:15 AM

Subject: RE: Request for license to daclatasvir, asunaprevir, BMS-791325 and daclatasvir/asunaprevir/BMS-791325 patents for territory of Romania.

To: "thiru@keionline.org" <thiru@keionline.org>

Dear Mr. Balasubramaniam,

Thank you for your letter dated July 29, 2014 regarding your request for a license to daclatasvir, asunaprevir, BMS-791325 and daclatasvir/asunaprevir/BMS-791325 patents for the territory of Romania. Bristol-Myers Squibb has been a leader for several decades in virology and has a strong, demonstrated commitment to evolving the standard of care in HIV, HBV and most recently in HCV. We are excited about the treatment prospects that our HCV compounds may offer to patients around the world and we remain committed to collaboration with other stakeholders who share an interest in advancing access to disease prevention, diagnosis, care and treatment.

Bristol-Myers Squibb believes that HCV patients should have access to treatment options as deemed medically appropriate. Consistent with our long-standing commitment to access, the company is evaluating potential options to make relevant BMS HCV products available in Romania and around the world. It would be premature for us to comment at this time on specifics of our plans which are under development.

Bristol-Myers Squibb welcomes and appreciates the opportunity to engage in meaningful and productive dialog with other HCV stakeholders. We look forward to sharing our access plans for Romania in the coming months.

Sincerely,

Sunil Patel

Director, Global Policy & Government Affairs